Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli ...

A world-leading experimental dementia drug designed to prevent the disease before it begins will be trialled in Australia for ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Royal Melbourne Hospital (RMH) is one of more than a dozen sites around Australia taking part in the major global trial for ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Eli Lilly and Co. on Thursday announced three executive leadership transitions that the Indianapolis drugmaker said better ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...